CAR-T Meeting 2024 | Addressing the challenge of bridging therapy in CAR-T in order to improve patient outcomes
In this video, Peter Vandenberghe, MD, UZ Leuven, Leuven, Belgium, discusses the role of bridging therapy in the CAR T-cell therapy process. Previously, bridging therapy was only considered for high-risk patients or those at late stages of disease. However, it is now understood that patients achieving a partial response (PR) or complete response (CR) through bridging therapy exhibit better CAR-T outcomes. Prof. Vandenberghe highlights the need to integrate bridging therapy into CAR-T treatment and investigate the best type to decrease disease burden as much as possible before CAR-T infusion. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Sponsorship or research funding: Janssen – Cilag, Pfizer;
Honoraria for advisory boards/meeting attendance support/consultancy/speaker fees: Bristol-Myers-Squibb, Gilead, Janssen-Cilag, Miltenyi Biotec, Novartis.
